Although higher levels of VASH1 are associated with poorer prognosis for some cancers, this may be due to increased VASH1 feedback in vivo and inhibition of angiogenesis factors (VEGF, FGF-2, and VASH2) in the tumor microenvironment [31]. This evidence concerns the gene VASH1 and neoplasm.